English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech
Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant
Dec 03, 2021 14:00 HKT
中国抗体公布旗舰产品SM03完成在中国III期临床试验招募
Nov 30, 2021 20:52 HKT
中國抗體公佈旗艦產品SM03完成在中國III期臨床試驗招募
Nov 30, 2021 20:51 HKT
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
Nov 30, 2021 20:50 HKT
Jacobson Pharma Announces FY2022 Interim Results
Nov 26, 2021 19:39 HKT
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
Nov 26, 2021 18:26 HKT
휴머니젠, 영국흉부학회 2021년도 동계 회의에 접수된 초록 발표
Nov 26, 2021 16:00 HKT
Inaugural Asia Summit on Global Health successfully explores healthcare landscape
Nov 25, 2021 20:00 HKT
中国抗体受邀出席首届亚洲医疗健康高峰论坛
Nov 25, 2021 18:28 HKT
中國抗體受邀出席首屆亞洲醫療健康高峰論壇
Nov 25, 2021 18:27 HKT
Inaugural Asia Summit on Global Health opens today
Nov 24, 2021 18:00 HKT
行动基因与善觅宣布合并 展现香港医疗科技世界级潜力
Nov 22, 2021 16:59 HKT
行動基因與善覓宣佈合併 展現香港醫療科技世界級潛力
Nov 22, 2021 16:58 HKT
ACT Genomics and Sanomics Merge to Unleash Hong Kong's Global Potential in Healthcare Technology
Nov 22, 2021 16:57 HKT
휴머니젠, 3분기 및 2021년 9월 30일 종결되는 9개월간의 재무 결과 보고 및 기업보고서 발표
Nov 22, 2021 11:00 HKT
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用于治疗复发或难治性急性髓系白血病的中国 III 期临床试验第一例受试者成功入组
Nov 22, 2021 10:42 HKT
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用於治療復發或難治性急性髓系白血病的中國 III 期臨床試驗第一例受試者成功入組
Nov 22, 2021 10:41 HKT
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Nov 22, 2021 10:40 HKT
휴머니젠, 급성 이식편대 숙주병을 대상으로 렌질루맙의 효과 평가를 위한 임상 연구 협력 발표
Nov 22, 2021 10:00 HKT
重磅!B细胞CD22单抗SM03治疗类风湿关节炎临床研究结果最新公布!
Nov 18, 2021 19:11 HKT
Next >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: